Mode
Text Size
Log in / Sign up
N/A N=60 Randomized Single-blind Basic Science

Neuromodulation of Conscious Perception: Investigating Thalamic Roles Through Ultrasonic Stimulation

Thalamus

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcome: Primary: Change in Sensitivity Derived From the Signal Detection Theory (SDT) — 0.7452; 0.7419; 0.7520; 0.7120 units on a scale — p=0.02

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
LIFUP excitation (Device); LIFUP inhibition (Device)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Michigan
Primary completion
May 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Sensitivity Derived From the Signal Detection Theory (SDT)
0.7452; 0.7419; 0.7520; 0.7120 0.02 sig
PRIMARY
Change in Perceptual Criterion Derived From the Signal Detection Theory (SDT)
0.3008; 0.2092; 0.3113; 0.2770 0.20

Summary

The purpose of this study is to evaluate the role that the thalamus (the egg-shaped structure in the middle of your brain) plays in perception using a low-intensity ultrasound pulsation (LIFUP) device. The researchers expect to observe differential changes in the perceptual outcomes based on the LIFUP stimulation of different thalamic areas

Eligibility Criteria

Inclusion Criteria

  • Must be right-handed.
  • Must have normal or corrected-to-normal vision (while wearing contact lenses). Please note: persons who need eyeglasses to achieve 20/20 vision cannot be included in this study as eyeglasses cannot be worn during the study visit.
  • Must not be on any medications for any neurological, psychological, or psychiatric conditions.
  • Must be English speaking.
  • Must be capable of giving written informed consent.

Exclusion Criteria

  • Vision that is not 20/20, or vision that is not corrected to 20/20 while wearing contact lenses.

Please note: persons needing eyeglasses to achieve 20/20 vision cannot be included in this study as eyeglasses cannot be worn during the study visit.

  • History of significant head injury with loss of consciousness.
  • Learning disability or other developmental disorder.
  • Medication use for any neurological, psychological, or psychiatric conditions.
  • Any impairment (sensory or motor loss), activity, or situation that in the judgment of the study coordinator or Principal Investigators would prevent satisfactory completion of the study protocol.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT06083493). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search